Text Size

Evaluating Effectiveness of Educational Intervention to Help Physicians Address Inappropriate Patient Requests for Direct-to-Consumer Advertised Prescription Medications

This study has been completed.
Sponsor:
Collaborator:
US States Attorney General Consumer and Prescriber Education Grant Program
Information provided by:
American Medical Association
ClinicalTrials.gov Identifier:
NCT00915291
First received: June 5, 2009
Last updated: NA
Last verified: June 2009
History: No changes posted
  Purpose

The purpose of this study is to determine whether physicians can be educated to better handle inappropriate requests from patients for direct-to-consumer advertised prescription medications.


Condition Intervention
Lumbosacral Muscle Strain
 Other: Web-based educational modules

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Caregiver)
Official Title: Sound Prescribing Study - Assessing the Impact of Pharmaceutical Marketing and Promotional Practices on Physician Prescribing

Further study details as provided by American Medical Association:

Primary Outcome Measures:
  • Decision to prescribe celecoxib [ Designated as safety issue: No ]

Enrollment: 133
Study Start Date: May 2007
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Usual education
Participants randomized into the "no intervention" arm were not exposed to the web-based educational modules
Experimental: Web-based educational modules
Participants randomized into the intervention arm were exposed to the web-based educational modules
 Other: Web-based educational modules
Interactive case-based modules that includes video vignettes of clinical interactions between hypothetical patients interacting with physicians

Detailed Description:

Since changes in FDA regulation direct-to-consumer advertising (DTCA), pharmaceutical companies have expended increasing resources to market their products to the public. This has led to increased awareness of diseases and potential treatments, but it has also created more public demand for medications that may not be appropriate for a patient's clinical presentation. This study aims to provide physicians with the knowledge and skills required to help them address inappropriate DTCA medication requests from patients.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Resident physicians in internal medicine or family medicine specialties at participating study sites

Exclusion Criteria:

  • Completed less than 10 months of residency
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00915291

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
United States, Nebraska
Creighton University School of Medicine
Omaha, Nebraska, United States, 68131
United States, Pennsylvania
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, United States, 19104
United States, Texas
University of Texas at Houston Medical School
Houston, Texas, United States, 77030
Sponsors and Collaborators
American Medical Association
US States Attorney General Consumer and Prescriber Education Grant Program
Investigators
Principal Investigator: Audiey C Kao, MD, PhD American Medical Association
  More Information

No publications provided

Responsible Party: Audiey Kao, MD, PhD, American Medical Association
ClinicalTrials.gov Identifier: NCT00915291     History of Changes
Other Study ID Numbers: AMA-ES62
Study First Received: June 5, 2009
Last Updated: June 5, 2009
Health Authority: United States: Institutional Review Board

Keywords provided by American Medical Association:
medical education
clinical decisionmaking
pharmaceutical marketing

ClinicalTrials.gov processed this record on May 21, 2013